Cargando…

Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation

BACKGROUND: Dedifferentiated liposarcoma (DDLPS), a tumor that lacks effective treatment strategies and is associated with poor outcomes, expresses amplified MDM2 in the presence of wild-type p53. MDM2 ubiquitination of p53 facilitates its XPO1-mediated nuclear export, thus limiting p53 tumor suppre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zuco, Valentina, Pasquali, Sandro, Tortoreto, Monica, Brich, Silvia, Percio, Stefano, Dagrada, Gian Paolo, Colombo, Chiara, Sanfilippo, Roberta, Lauricella, Calogero, Gounder, Mrinal, El Bezawy, Rihan, Barisella, Marta, Dei Tos, Angelo Paolo, Casali, Paolo Giovanni, Gronchi, Alessandro, Stacchiotti, Silvia, Zaffaroni, Nadia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923610/ https://www.ncbi.nlm.nih.gov/pubmed/33648535 http://dx.doi.org/10.1186/s13046-021-01886-x

Ejemplares similares

miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer
por: Martini, Silvia, et al.
Publicado: (2021)

Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft
por: Stacchiotti, Silvia, et al.
Publicado: (2019)

Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft
por: Zuco, Valentina, et al.
Publicado: (2023)

Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma
por: Alessandrini, Irene, et al.
Publicado: (2022)

miR-1272 Exerts Tumor-Suppressive Functions in Prostate Cancer via HIP1 Suppression
por: Rotundo, Federica, et al.
Publicado: (2020)

Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin
por: Fabbroni, Chiara, et al.
Publicado: (2021)

SPOP Deregulation Improves the Radiation Response of Prostate Cancer Models by Impairing DNA Damage Repair
por: El Bezawy, Rihan, et al.
Publicado: (2020)

High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma
por: Sanfilippo, Roberta, et al.
Publicado: (2014)

miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCε and ZEB1 inhibition
por: El Bezawy, Rihan, et al.
Publicado: (2019)

Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib
por: Stacchiotti, Silvia, et al.
Publicado: (2012)

Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism
por: El Bezawy, Rihan, et al.
Publicado: (2017)

Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma
por: Gounder, Mrinal, et al.
Publicado: (2021)

miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma
por: El Bezawy, Rihan, et al.
Publicado: (2022)

Identification of a gene expression driven progression pathway in myxoid liposarcoma
por: De Cecco, Loris, et al.
Publicado: (2014)

Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma
por: Colia, Vittoria, et al.
Publicado: (2017)

Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review
por: Colia, Vittoria, et al.
Publicado: (2016)

NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas
por: Brenca, Monica, et al.
Publicado: (2019)

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
por: Gounder, Mrinal M., et al.
Publicado: (2022)

High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma
por: Colia, Vittoria, et al.
Publicado: (2017)

When does a new sarcoma exist?
por: Casali, Paolo G., et al.
Publicado: (2020)

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2017)

Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma
por: Urbini, Milena, et al.
Publicado: (2018)

Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue
por: Urbini, Milena, et al.
Publicado: (2017)

Long‐term survivors with desmoplastic small round cell tumor (DSRCT): Results from a retrospective single‐institution case series analysis
por: Giani, Claudia, et al.
Publicado: (2023)

Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients
por: Affatato, Roberta, et al.
Publicado: (2020)

MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer
por: Doldi, Valentina, et al.
Publicado: (2021)

The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial–mesenchymal transition, and immune response
por: Devecchi, Andrea, et al.
Publicado: (2018)

Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients
por: Baldi, Giacomo G, et al.
Publicado: (2013)

Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework
por: Bozzi, Fabio, et al.
Publicado: (2016)

Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs
por: Punzi, Simona, et al.
Publicado: (2019)

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2019)

Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2020)

Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice
por: Choi, Yunsik, et al.
Publicado: (2018)

Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma
por: Thirasastr, Prapassorn, et al.
Publicado: (2022)

Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics
por: Guilhamon, Paul, et al.
Publicado: (2014)

Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new
por: Frezza, Anna Maria, et al.
Publicado: (2017)

Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting
por: Frezza, Anna Maria, et al.
Publicado: (2017)

Selinexor for multiple myeloma
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5rtov6rffs5vq1uo9kt6do5r17